Antiviral agents against influenza viruses

Research output: Contribution to journalReview article

10 Citations (Scopus)

Abstract

In annual epidemics and occasional pandemics, influenza viruses cause acute respiratory illnesses in infected humans. Vaccines and antiviral drugs are two main arsenals available for a fight against influenza viruses. However, vaccines often exhibit a limited efficacy in high risk populations, and antiviral drugs are always concerned for mutations, which confer viral resistance. Here we review current advances and knowledge in relation to the usage of antiviral drugs as a prophylactic or therapeutic and the mechanism of resistant variants mainly against the neuraminidase inhibitors. Comprehensive understanding of the resistant mechanism will pave a road for developing new antivirals and/or finding medical or natural alternatives inducing less frequent resistance, and application of combination therapy using two or three different kinds of antivirals can suggest a useful medical intervention against both of seasonal and highly pathogenic influenza viruses including resistant variants. In this review, we provide insights of antiviral drugs for the control and prevention of influenza viruses.

Original languageEnglish
Pages (from-to)284-293
Number of pages10
JournalJournal of Bacteriology and Virology
Volume42
Issue number4
DOIs
Publication statusPublished - 2012 Jan 1
Externally publishedYes

Fingerprint

Orthomyxoviridae
Antiviral Agents
Vaccines
Drug and Narcotic Control
Neuraminidase
Pandemics
Mutation
Therapeutics
Population

Keywords

  • Antiviral drugs
  • Combination therapy
  • Influenza
  • Neuraminidase
  • Resistance

ASJC Scopus subject areas

  • Microbiology
  • Immunology
  • Virology

Cite this

Antiviral agents against influenza viruses. / Park, Sehee; Kim, Jin Il; Park, Man-Seong.

In: Journal of Bacteriology and Virology, Vol. 42, No. 4, 01.01.2012, p. 284-293.

Research output: Contribution to journalReview article

@article{fb773c29e96c409ba05fefd839a11029,
title = "Antiviral agents against influenza viruses",
abstract = "In annual epidemics and occasional pandemics, influenza viruses cause acute respiratory illnesses in infected humans. Vaccines and antiviral drugs are two main arsenals available for a fight against influenza viruses. However, vaccines often exhibit a limited efficacy in high risk populations, and antiviral drugs are always concerned for mutations, which confer viral resistance. Here we review current advances and knowledge in relation to the usage of antiviral drugs as a prophylactic or therapeutic and the mechanism of resistant variants mainly against the neuraminidase inhibitors. Comprehensive understanding of the resistant mechanism will pave a road for developing new antivirals and/or finding medical or natural alternatives inducing less frequent resistance, and application of combination therapy using two or three different kinds of antivirals can suggest a useful medical intervention against both of seasonal and highly pathogenic influenza viruses including resistant variants. In this review, we provide insights of antiviral drugs for the control and prevention of influenza viruses.",
keywords = "Antiviral drugs, Combination therapy, Influenza, Neuraminidase, Resistance",
author = "Sehee Park and Kim, {Jin Il} and Man-Seong Park",
year = "2012",
month = "1",
day = "1",
doi = "10.4167/jbv.2012.42.4.284",
language = "English",
volume = "42",
pages = "284--293",
journal = "Journal of Bacteriology and Virology",
issn = "1598-2467",
publisher = "Chonnam National University Medical School",
number = "4",

}

TY - JOUR

T1 - Antiviral agents against influenza viruses

AU - Park, Sehee

AU - Kim, Jin Il

AU - Park, Man-Seong

PY - 2012/1/1

Y1 - 2012/1/1

N2 - In annual epidemics and occasional pandemics, influenza viruses cause acute respiratory illnesses in infected humans. Vaccines and antiviral drugs are two main arsenals available for a fight against influenza viruses. However, vaccines often exhibit a limited efficacy in high risk populations, and antiviral drugs are always concerned for mutations, which confer viral resistance. Here we review current advances and knowledge in relation to the usage of antiviral drugs as a prophylactic or therapeutic and the mechanism of resistant variants mainly against the neuraminidase inhibitors. Comprehensive understanding of the resistant mechanism will pave a road for developing new antivirals and/or finding medical or natural alternatives inducing less frequent resistance, and application of combination therapy using two or three different kinds of antivirals can suggest a useful medical intervention against both of seasonal and highly pathogenic influenza viruses including resistant variants. In this review, we provide insights of antiviral drugs for the control and prevention of influenza viruses.

AB - In annual epidemics and occasional pandemics, influenza viruses cause acute respiratory illnesses in infected humans. Vaccines and antiviral drugs are two main arsenals available for a fight against influenza viruses. However, vaccines often exhibit a limited efficacy in high risk populations, and antiviral drugs are always concerned for mutations, which confer viral resistance. Here we review current advances and knowledge in relation to the usage of antiviral drugs as a prophylactic or therapeutic and the mechanism of resistant variants mainly against the neuraminidase inhibitors. Comprehensive understanding of the resistant mechanism will pave a road for developing new antivirals and/or finding medical or natural alternatives inducing less frequent resistance, and application of combination therapy using two or three different kinds of antivirals can suggest a useful medical intervention against both of seasonal and highly pathogenic influenza viruses including resistant variants. In this review, we provide insights of antiviral drugs for the control and prevention of influenza viruses.

KW - Antiviral drugs

KW - Combination therapy

KW - Influenza

KW - Neuraminidase

KW - Resistance

UR - http://www.scopus.com/inward/record.url?scp=84922686847&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84922686847&partnerID=8YFLogxK

U2 - 10.4167/jbv.2012.42.4.284

DO - 10.4167/jbv.2012.42.4.284

M3 - Review article

AN - SCOPUS:84922686847

VL - 42

SP - 284

EP - 293

JO - Journal of Bacteriology and Virology

JF - Journal of Bacteriology and Virology

SN - 1598-2467

IS - 4

ER -